Rossi Luigia, Fraternale Alessandra, Bianchi Marzia, Magnani Mauro
Department of Biomolecular Sciences, University of Urbino "Carlo Bo", Urbino, Italy.
EryDel SpA, Bresso, Italy.
Front Physiol. 2019 Aug 20;10:1070. doi: 10.3389/fphys.2019.01070. eCollection 2019.
Red blood cells (RBC) are actually exploited as innovative drug delivery systems with unconventional and convenient properties. Because of a long survival and a non-random removal from circulation, RBC can be loaded with drugs and/or contrasting agents without affecting these properties and maintaining the original immune competence. However, native or drug-loaded RBC, can be modified decorating the membrane with peptides, antibodies or small chemical entities so favoring the targeting of the processed RBC to specific cells or organs. Convenient modifications have been exploited to induce immune tolerance or immunogenicity, to deliver antibodies capable of targeting other cells, and to deliver a number of constructs that can recognize circulating pathogens or toxins. The methods used to induce membrane processing useful for biomedical applications include the use of crosslinking agents and bifunctional antibodies, biotinylation and membrane insertion. Another approach includes the expression of engineered membrane proteins upon transfection of immature erythroid precursors with lentiviral vectors, followed by expansion and differentiation into mature erythrocytes before administration to a patient in need. Several applications have now reached the clinic and a couple of companies that take advantage from these properties of RBC are already in Phase 3 with selected applications. The peculiar properties of the RBC and the active research in this field by a number of qualified investigators, have opened new exciting perspectives on the use of RBC as carriers of drugs or as cellular therapeutics.
红细胞(RBC)实际上被用作具有非常规且便利特性的创新药物递送系统。由于其生存期长且从循环中被非随机清除,红细胞可以装载药物和/或造影剂,而不会影响这些特性并保持原始免疫能力。然而,天然或载药红细胞可以通过用肽、抗体或小化学实体修饰膜来进行改造,从而有利于将处理后的红细胞靶向特定细胞或器官。已经利用了便利的修饰来诱导免疫耐受或免疫原性,递送能够靶向其他细胞的抗体,并递送许多能够识别循环病原体或毒素的构建体。用于诱导对生物医学应用有用的膜处理的方法包括使用交联剂和双功能抗体、生物素化和膜插入。另一种方法包括在用慢病毒载体转染未成熟红细胞前体后表达工程化膜蛋白,然后在给予有需要的患者之前将其扩增并分化为成熟红细胞。现在有几种应用已经进入临床,并且有几家利用红细胞这些特性的公司在选定的应用方面已经进入了三期临床试验。红细胞的独特特性以及许多合格研究人员在该领域的积极研究,为将红细胞用作药物载体或细胞疗法开辟了新的令人兴奋的前景。